Bristol-Myers agrees to pay $499M to settle probes

Plagued by probes into its questionable sales and marketing practices, Bristol-Myers Squibb has tentatively agreed to pay $499 million to settle up with the Justice Department and the U.S. Attorney for Massachusetts. Bristol-Myers has also agreed to sign a corporate integrity agreement with the feds but will not face criminal charges. Final details of the agreement still have to be worked out.

- check out the company's release on the settlement
- here's the report on BMS from MarketWatch

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.